Pharmacy bag

KKR acquires minority stake in Gland Pharma

KKR is to acquire a minority stake in Gland Pharma, an Indian pure-play generic injectable pharmaceutical products company, for approximately USD200m.

This includes KKR acquiring the entire stake held by Evolvence India Life Sciences Fund (EILSF), an existing private equity investor in Gland Pharma.
 
Established in 1978 and based in Hyderabad, Gland Pharma develops and manufactures generic injectables primarily for the US market and also for India and other semi-regulated markets. In 2003, Gland Pharma was the first company in India to get US Food and Drug Administration (FDA) approval for pharmaceutical liquid injectable products. Gland Pharma has also pioneered pre-filled syringe technology in India and exports products in this format to the US market.
 
Gland Pharma founder-chairman P V N Raju says: “Gland Pharma is at an important juncture in its evolution where we have proven our sterile manufacturing capabilities, established ourselves as a high-quality manufacturer of complicated injectables products and achieved a track-record of strong financial performance. Our partnership with KKR will help us in our next phase of growth as we look to materially expand our manufacturing capacities and invest more in our development work with the goal of expanding our product registrations.”
 
KKR India chief executive Sanjay Nayar says: “Gland Pharma has a track record of strong financial performance as well as long-standing relationships with Indian and international pharmaceutical companies and we believe there is significant potential for it to grow these partnerships even further. We are excited to invest behind a high-quality promoter family and management team led by Dr. Ravi. We look forward to working closely with them to help build out the business and create value for all stakeholders.”
 
KKR’s investment in Gland Pharma represents its fourth announced investment from the KKR Asian II Fund and its second overall private equity investment in India in 2013. The transaction is subject to regulatory approvals and other customary closing conditions.

Further reading



Upcoming events

1 day 57 min from now - Amsterdam
2 days 57 min from now - London
1 week 2 days from now - London
1 week 2 days from now - London
1 week 2 days from now - Cartegena

Upcoming training